Fort Lauderdale, Fla., - KKS (Coordination Center for Clinical Trials) DuÌsseldorf, an academic center in Europe, has signed a multiyear agreement with OmniComm Systems, Inc., a global provider of electronic data capture (EDC) and clinical data management solutions. Under the agreement, Heinrich Heine University
DuÌsseldorf will use OmniComm’s TrialMaster EDC technology to develop and conduct clinical trials at multiple sites. As a key division of
the Faculty of Medicine at Heinrich Heine University, KKS supports clinical research trials undertaken at the institution.
In addition to building new clinical trials in TrialMaster, the university will migrate a number of ongoing trials to the TrialMaster platform. The
agreement provides KKS with the opportunity to enhance the efficiency and effectiveness of its clinical trials. KKS selected OmniComm
because of TrialMaster’s inherent flexibility and broad capabilities to support clinical trials across all phases of clinical development.
“We are honored to be partnering with KKS in supporting such a prestigious University as they strive to improve the quality of clinical trials
and continue to develop further competence in the academic sector,” said Stephen Johnson, president and CEO of OmniComm.
About KKS DuÌsseldorf
The Coordination Center for Clinical Trials (KKS) is a central element of the Faculty of Medicine at DuÌsseldorf’s Heinrich Heine University.
The KKS supports clinical, primarily multi-center trials taking into consideration Good Clinical Practice (GCP) and academic criteria, relating
to both admission-relevant trials and exclusively academically focused trials. KKS also organizes and holds training events on the subject
of clinical trials. Please visit https://www.uniklinik-duesseldorf.de/en/coordination-center-for-clinical-trials for more information.
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to
helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical
centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, research
organizations drive efficiency in clinical development, better manage risks, ensure regulatory compliance and manage their clinical
operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from
more than 6,000 clinical trials. Please visit www.omnicomm.com for more information, and follow OmniComm on Twitter:
@OmniCommSystems, on LinkedIn: @OmniComm Systems and Facebook: @OmniComm Systems, Inc.
Trademarks
OmniComm, TrialMaster and TrialOne are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their
respective owners.
Contact Info
Kuno van der Post, Ph.D.
OmniComm Systems, Inc.
+1.954.473.1254
KvanderPost@omnicomm.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.